FrostPharma strengthen its product portfolio with Betapred
FrostPharma strengthen its product portfolio in the Nordics by including Betapred (betametasone) from the 1st of April, 2023.
FrostPharma strengthen its product portfolio in the Nordics by including Betapred (betametasone) from the 1st of April, 2023.
During her tenure as CEO for FrostPharma AB, Cecilia Bröms-Thell has invested and prepared the FrostPharma business for accelerated growth while securing solid performance of the in-line portfolio. The Regulatory framework and the Commercial capabilities have been strengthened and FrostPharma is now in a position to From the 1st of January 2022 Fredrik Andersch take the role of FrostPharma CEO.
FrostPharma is proud and pleased to announce that the company has been successful in the tender bidding process in Norway. The company has been notified of winning two national tender contracts in two different therapeutic areas, starting Feb 1, 2022 and running for two years with option to prolong another two years.
Apoteket AB har valt att byta ut sitt sortiment av doseringshjälpmedel till FrostPharma's återvinningsbara produkter i bioplast. Produkterna är tillverkade av 100% återvinningsbar bioplast, producerade i Sverige och levereras i en miljövänlig kartong.
FrostPharmas nuvarande VD och största enskilda ägare, Clas Lindbergson, avgår som VD. Istället ska han satsa helhjärtat på bolagets affärsutveckling. Den nya att ta över rodret är Cecilila Bröms-Thell som påbörjar tjänsten from 1 januari 2021.
Din Pharma-partner i Europa! Tillsammans med det oberoende läkemedelsföretaget TwinPharma (Nederländerna) har FrostPharma nu gått samman i Your Pharma Partner in Europe Alliance.